Back to results
US 2003/0113305 A1Published application
Compositions and methods for treating diabetes
AssigneeUniversity of Washington
InventorsWilliam R.A. Osborne, Nagarajan Ramesh
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Washington
InventorsWilliam R.A. Osborne, Nagarajan Ramesh
Estimating the term…
The present invention provides an isolated population of cells containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention also provides an isolated population of cells which further express a hexosamine synthetic pathway enzyme. The invention additionally provides vectors containing an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving the proinsulin cleavage site to produce insulin. The invention further provides a method of treating or preventing diabetes by implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving the proinsulin cleavage site to produce insulin.
An isolated population of cells comprising an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site and a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving said proinsulin cleavage site to produce insulin.
A three-gene vector comprising an expressible nucleic acid encoding proinsulin containing a proinsulin cleavage site, a glucose-regulated expressible nucleic acid encoding a protease capable of cleaving said proinsulin cleavage site to produce insulin, and a selectable marker.
A method of treating or preventing diabetes comprising implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site and a glucose-regulated protease capable of cleaving said proinsulin cleavage site to produce insulin.
A method of treating or preventing diabetes comprising implanting into an individual cells coexpressing proinsulin containing a proinsulin cleavage site, a glucose-regulated protease capable of cleaving said proinsulin cleavage site to produce insulin, and a hexosamine biosynthetic pathway enzyme.
Dependencies are inferred from the claim text.